New combo approach for MS: switching from natalizumab to cladribine
NCT ID NCT04178005
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether switching from natalizumab to cladribine tablets is safe and effective for people with relapsing forms of multiple sclerosis. About 40 adults aged 18-60 will take cladribine after stopping natalizumab. Researchers will track immune cell changes, relapse rates, and nerve damage markers over 24 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
College Park Family Care Center Physicians Group
Overland Park, Kansas, 66212, United States
-
UT Southwestern Medical center
Dallas, Texas, 75390, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we decode the different types of pain in multiple sclerosis?
- Can a blood pressure pill slow MS disability?
- Hidden MS progression: can brain scans and blood tests predict it?
- Can Brain-Training apps fix sleep in MS?
- Can an Iron-Based dye reveal hidden inflammation in progressive MS?
- Strumming for the brain: could ukulele lessons sharpen minds in MS?